ArticleThe European respiratory journal2016
"Scar-cinoma": viewing the fibrotic lung mesenchymal cell in the context of cancer biology.
Article in The European respiratory journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Pooled it
- Beyond slowing decline: leveraging apoptotic synergy to reverse pulmonary fibrosis.American journal of respiratory cell and molecular biology · 2026Article
- MCT4 mediates hypoxia-induced extracellular lactate release from IPF fibroblasts.American journal of respiratory cell and molecular biology · 2026Article
- Predictors of distant, local and lymph node recurrence for surgically treated non-small cell lung cancer (NSCLC) patients: Retrospective analysis of pathological T1-4, N0, R0, M0 tumor stages.Pneumologie (Stuttgart, Germany) · 2026Article
- Article
- Comparison of Gastric Cancer Models Using Different Dimensions In Vitro.Cancer reports (Hoboken, N.J.) · 2025Article
- From Worms to Tumors: Conserved Strategies of Cellular Arrest and Survival Governing Dormancy.Cancer research · 2025Review
- Interstitial Lung Diseases and Lung Cancer: A Review on Similarities, Common Pathogenesis and Therapeutic Approach.Journal of personalized medicine · 2025Review
- TheJournal of clinical medicine · 2024Review
- A New Strategy to Inhibit Scar Formation by Accelerating Normal Healing Using Silicate Bioactive Materials.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- SPP1 induces idiopathic pulmonary fibrosis and NSCLC progression via the PI3K/Akt/mTOR pathway.Respiratory research · 2024Article
- Research progress of SIRTs activator resveratrol and its derivatives in autoimmune diseases.Frontiers in immunology · 2024Review
- An Interesting Sequel of Pulmonary Tuberculosis.Cureus · 2023Article
- Exploration of the shared genes and signaling pathways between lung adenocarcinoma and idiopathic pulmonary fibrosis.Journal of thoracic disease · 2023Article
- Idiopathic pulmonary fibrosis and lung cancer: future directions and challenges.Breathe (Sheffield, England) · 2022Review
- [Research Progress on the Pathogenesis of Lung Cancer Associated with Idiopathic Pulmonary Fibrosis].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Review
- High complement protein C1q levels in pulmonary fibrosis and non-small cell lung cancer associated with poor prognosis.BMC cancer · 2022Article
- Acute Exacerbation of Idiopathic Pulmonary Fibrosis with Lung Cancer: A Comparative Analysis of the Incidence, Survival Rate, and CT Findings with the Patients without Lung Cancer.Taehan Yongsang Uihakhoe chi · 2020Article
- Scar carcinoma - a real entity or a historical 'histological curiosity'?African journal of thoracic and critical care medicine · 2020Article
- Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
Abstract
Lung cancer and pulmonary fibrosis are common, yet distinct, pathological processes that represent urgent unmet medical needs. Striking clinical and mechanistic parallels exist between these distinct disease entities. The goal of this article is to examine lung fibrosis from the perspective of cancer-associated phenotypic hallmarks, to discuss areas of mechanistic overlap and distinction, and to highlight profibrotic mechanisms that contribute to carcinogenesis. Ultimately, we speculate that such comparisons might identify opportunities to leverage our current understanding of the pathobiology of each disease process in order to advance novel therapeutic approaches for both. We anticipate that such "outside the box" concepts could be translated to a more precise and individualised approach to fibrotic diseases of the lung.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.